Key result
Post-AMI survivors with newer-generation DES face a ~28% cumulative risk of MACEs through 7 years.
Why the study?
Although acute myocardial infarction treatments have improved outcomes during the first year, less was known about the subsequent risks of recurrent cardiovascular events and mortality in 1-year survivors implanted with newer-generation drug-eluting stents.
Observational (n=5,397)
Yes
In 1-year survivors of AMI treated with newer-generation DES, the long-term risks of MACE and death remain high and are strongly influenced by uncontrolled blood pressure, LDL-C, and recurrent events within the first year.
Answers are grounded in this paper and cite their sources.
High residual MACE and mortality risks persist in 1-year AMI survivors; hypothesis-generating for targeted secondary prevention trials.
Current treatments for acute myocardial infarction (AMI) have dramatically improved clinical outcomes during the first year after AMI. Less is known, however, about the subsequent risks of recurrent cardiovascular events and mortality in patients who survive 1 year after AMI. The purpose of the present study is to evaluate long-term clinical outcomes in 1-year AMI survivors who were implanted with newer-generation drug-eluting stents (DESs) since 2010. The COREA-AMI (CardiOvascular Risk and idEntificAtion of potential high-risk population in AMI) registry consecutively enrolled AMI patients who underwent percutaneous coronary intervention (PCI), and patients who received newer-generation DESs since 2010 were analyzed. The primary endpoint was major adverse cardiovascular events (MACEs), and secondary endpoint was all-cause mortality. Of 6242 AMI patients, 5397 were alive 1 year after the index procedure. The cumulative incidence of MACEs and all-cause death 1 to 7 years after AMI were 28.4% (annually 4-6%) and 20.2% (annually 3-4%), respectively. Multivariate analysis showed that uncontrolled systolic blood pressure (SBP) and serum low-density lipoprotein cholesterol (LDL-C) concentration, as well as traditional risk factors, were associated with MACEs and all-cause death. Recurrent non-fatal myocardial infarction, ischemic stroke, and bleeding events within 1 year were significantly associated with all-cause death. The risks of adverse cardiovascular events and death remain high in AMI patients more than 1 year after the index PCI with newer-generation DESs. Traditional risk factors, uncontrolled SBP and LDL-C, and non-fatal adverse events within 1 year after the index procedure strongly influence long-term clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2021) conducted an observational in Acute myocardial infarction (1-year survivors implanted with newer-generation drug-eluting stents) (n=5,397). Newer-generation drug-eluting stent implantation in 1-year AMI survivors was evaluated on Major adverse cardiovascular events (MACEs: cardiovascular death, non-fatal MI, non-fatal ischemic stroke, and any revascularization) from 1 to 7 years after index PCI. One-year survivors of AMI implanted with newer-generation DESs had a 1-to-7-year cumulative incidence of MACEs of 28.4% and all-cause mortality of 20.2%.
Synapse has enriched 10 related papers. Consider them for comparative context: